



## **Press Release**

### **TxCell to participate at the 2015 French Life Sciences Day, New York, US**

**Valbonne, France, June 17, 2015 – TxCell SA (FR0010127662 – TXCL)**, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it will participate at the second French Life Sciences Days in New York, on June 17-18, 2015. The investor's conference will be held at W Hotel, 541 Lexington Avenue, New York on Thursday, June 18.

This event is organized by France Biotech. TxCell also participated at the inaugural French Life Sciences Days in 2014, which attracted more than 50 American investors and the organization of 70 face-to-face meetings. This event aims to bring together French Life Sciences companies listed on stock market with the North American financial community. During the 2015 Life Science Days, TxCell and 17 other French biotechnology and medical technology companies listed on the French stock market will present and hold face-to-face meetings with specialized North American investments funds, banks, financial analysts and media.

Stephane Boissel, CEO, TxCell will present an update on TxCell's ASTrIA technology platform and its personalized cellular immunotherapy programs for the treatment of several severe chronic inflammatory and autoimmune diseases.

"The body of scientific evidence that T regulatory cells could play as big role in autoimmunity and chronic inflammation as T effector cells in oncology is continuing to grow. This is one key reason for the level of interest that TxCell is generating amongst those attending the France Biotech Life Sciences Days and other events," said Stephane Boissel, CEO TxCell. "This interest provides additional encouragement for us both individually and with partners to accelerate the development of TxCell's platforms and product portfolio."

### **About the "French Life Science Days"**

This second edition aims at fostering and boosting the connections between French listed companies and investors worldwide in an effort to facilitate exchanges and demonstrate the solidity of our own financial community. This "French Life Science days" initiative brings together key Parisian players (brokers, analysts, auditors, lawyers and communication agencies) to form a sponsorship committee that will support life sciences entrepreneurs. During this occasion, the French biotech companies listed on the Euronext exchange will introduce themselves to international investors.

### **About France Biotech**

France Biotech brings together the main French life science companies and their expert partners. Its mission is to support the development of the French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate for the French innovative sector. The organization is currently chaired by Pierre-Olivier Goineau. France Biotech has over 200 members and its board of directors is composed of 20 entrepreneurs in the life sciences. For more information: [www.france-biotech.org](http://www.france-biotech.org)

### **About TxCell**

TxCell develops innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave® in refractory Crohn's disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell's second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. Listed on the regulated market Euronext Paris, TxCell is a spin-off of Inserm (France's National Institute for Health and Medical Research). TxCell has 70 employees based both at the headquarters located in the Sophia Antipolis technology park, Nice, France and at its manufacturing site in Besançon. For further information visit [www.txcell.com](http://www.txcell.com)

### **Practical Information about TxCell shares:**

**ISIN code** FR0010127662

**Ticker code** TXCL

**Disclaimer:**

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.

**CONTACTS**

<b>TxCell</b>	<b>Image Box – Press relations</b>	<b>NewCap – Investor relations</b>
BD & Communication Department Tel: +33(0) 497 218 300 Fax: +33(0) 493 641 580 <a href="mailto:contact@txcell.com">contact@txcell.com</a>	Neil Hunter / Emma Marshall Tel: +44(0) 20 8943 4685 <a href="mailto:emma.marshall@imageboxpr.co.uk">emma.marshall@imageboxpr.co.uk</a> <a href="mailto:neil.hunter@imageboxpr.co.uk">neil.hunter@imageboxpr.co.uk</a>	Julien Perez / Pierre Laurent Tel: +33 (0)1 44 71 98 52 <a href="mailto:txcell@newcap.fr">txcell@newcap.fr</a>